beta

CYAD

Celyad SA

Cyad

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Market Cap: 124 Million

Primary Exchange: NASDAQ

Website: http://www.celyad.com

Shares Outstanding: 13.9 Million

Float:

Dividend: (%)

Beta: 1.104120940494

Sector: Health Technology

Industry: Pharmaceuticals: Other

Short Interest (Jan 12, 2018): 82.8 Thousand

Ethical Flags

Animal testing

Longest drawdown: 791 trading days

From: 2017-10-05 To: 2019-11-12

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud